Is Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Indivior Pharmaceuticals, Inc. at current levels.
Sublocade is becoming the standard of care for opioid addiction, and Indivior is finally being run like the franchise it owns.
Where INDV is headed
Indivior in mid-2028 looks like a different company than the one that limped into 2025 with shareholder revolts, a CEO exit, and a stock at $13. Sublocade, the once-monthly buprenorphine injection, is on track to exit 2027 at a $1.7B-$1.9B annual run-rate, with US treatment center penetration crossing 35% and criminal justice system contracts (the unsexy but enormous channel where opioid-dependent inmates are released straight into Sublocade scripts) providing a steady, non-cyclical demand floor. The product is becoming the default first-line treatment, displacing daily Suboxone film not because doctors prefer it ideologically but because retention rates are roughly double and the operational overhead for clinics collapses when patients show up once a month instead of every week.
Read the full Compass Direction on INDV
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $38.01).
See the full INDV analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Indivior Pharmaceuticals, Inc. at current levels. Sublocade is becoming the standard of care for opioid addiction, and Indivior is finally being run like the franchise it owns.
What is INDV's Compass Score?
Indivior Pharmaceuticals, Inc. scores 76/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for INDV?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the INDV page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.